Avenciguat(Avenciguat) - 药物靶点：sGC_在研适应症：系统性硬皮病，弥漫性硬皮病_专利_临床

概要

基本信息

药物类型

小分子化药

别名

BI 685509、BI-685509、BI685509

靶点

sGC

作用方式

刺激剂

作用机制

sGC刺激剂(可溶性鸟苷酸环化酶复合体刺激剂)

治疗领域

免疫系统疾病皮肤和肌肉骨骼疾病其他疾病

在研适应症

系统性硬皮病弥漫性硬皮病

非在研适应症

代偿期肝硬化糖尿病肾病食管胃静脉曲张+ [8]

原研机构

Boehringer Ingelheim GmbH

在研机构

Boehringer Ingelheim Pharma GmbH & Co., KG

Boehringer Ingelheim GmbH

勃林格殷格翰（中国）投资有限公司

非在研机构

Boehringer Ingelheim International GmbHAlmac Pharma Services Ltd.

权益机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)临床2期

特殊审评孤儿药 (美国)、孤儿药 (欧盟)

登录后查看时间轴

结构/序列

分子式C34H38N4O5

InChIKeyKWNFFNFBUMFTHK-UHFFFAOYSA-N

CAS号1579514-06-9

关联

15

项与 Avenciguat 相关的临床试验

NCT06272058

/ Terminated临床1期

Pharmacokinetics, Safety, and Tolerability of BI 685509 in Subjects With Severe Liver Impairment (Child-Pugh Classification C) as Compared to Healthy Subjects

This study is open to people with and without severe liver problems. People can join the study if they are 18 to 80 years of age and have a body mass index (BMI) between 18.5 and 42 kg/m2.
Avenciguat (BI 685509) is a medicine that is being developed to treat high blood pressure in the portal vein (main vessel going to the liver). The purpose of this study is to find out whether having liver problems influences how Avenciguat (BI 685509) is taken up in the body. All participants take Avenciguat (BI 685509) once as a tablet.
Participants are in the study for slightly longer than 1 month. Following the screening period of about 4 weeks, they stay at the study site for 4 nights. Afterwards, there are 2 visits to the study site. The site staff measures the amount of Avenciguat (BI 685509) in the blood. The doctors also regularly check participants' health and take note of any unwanted effects.

开始日期2024-05-03

申办/合作机构

Boehringer Ingelheim GmbH

NCT06193811

/ Completed临床1期

Relative Bioavailability of Two Different Tablet Formulations of BI 685509 and Investigation of the Effects of Food and Esomeprazole on the Pharmacokinetics of BI 685509 Following Oral Administration in Healthy Male and Female Subjects (an Open-label, Randomised, Four-way Crossover Trial)

The main objective of this trial is to investigate:
* the relative bioavailability of Avenciguat (BI 685509) TF2 (Reference, R) vs. Avenciguat (BI 685509) iCF (Test 1, T1) tablets under fasted conditions
* the relative bioavailability of Avenciguat (BI 685509) iCF tablets under fasted (T1) and fed (Test 2, T2) conditions
* the relative bioavailability of Avenciguat (BI 685509) iCF tablets given alone (T1) and together with esomeprazole (Test 3, T3) under fasted conditions

开始日期2024-01-16

申办/合作机构

Boehringer Ingelheim GmbH

NCT06082843

/ Terminated临床2期

Randomised, Double-blind, Placebo-controlled and Parallel Group Trial to Investigate the Effects of One Dose (Up-titration to a Fixed Dose Regimen) of Oral BI 685509 on Portal Hypertension After 8 Weeks Treatment in Patients With Clinically Significant Portal Hypertension (CSPH) in Decompensated Cirrhosis After Their First Decompensation Event, Who Are Stabilized CTP 5-7

This study is open to adults with advanced liver cirrhosis caused by hepatitis B, hepatitis C, alcohol-related liver disease, non-alcoholic steatohepatitis or other causes. People can join the study if they have high blood pressure in the portal vein (main vessel going to the liver) and bleeding in the esophagus or fluid accumulation in the belly. The purpose of this study is to find out whether a medicine called avenciguat helps people with this condition.
Participants are put into 2 groups by chance. One group takes avenciguat tablets and the other group takes placebo tablets. Placebo tablets look like avenciguat tablets but do not contain any medicine. Participants take a tablet twice a day for 8 weeks.
Participants are in the study for 2 to 3 months. During this time, they visit the study site regularly. At 2 of the visits, the doctors check the pressure in the liver vein by inserting a catheter (a long thin tube) that gives information about pressure in the portal vein. The change in blood pressure is then compared between the 2 groups to see whether the treatment works. The doctors also regularly check participants' health and take note of any unwanted effects.

开始日期2024-01-03

申办/合作机构

Boehringer Ingelheim GmbH

100 项与 Avenciguat 相关的临床结果

登录后查看更多信息

100 项与 Avenciguat 相关的转化医学

登录后查看更多信息

100 项与 Avenciguat 相关的专利（医药）

登录后查看更多信息

11

项与 Avenciguat 相关的文献（医药）

2026-01-02·EXPERT OPINION ON INVESTIGATIONAL DRUGS

Mass balance and absolute bioavailability of avenciguat ( ¹⁴ C) after intravenous or oral administration in healthy male participants

Article

作者: Joseph, David ; Herich, Lena ; Gao, Eric ; Mitra, Pallabi ; Auclair, Adam M. ; Wolfgang, Taylor ; Wong, Diane ; Tiessen, Renger

BACKGROUND:

Avenciguat, a potent nitric oxide-independent activator of soluble guanylyl cyclase, is being evaluated in chronic kidney disease and systemic sclerosis. We assessed avenciguat absolute bioavailability and mass balance.

RESEARCH DESIGN AND METHODS:

Open-label Phase 1 trial in healthy men. Doses: Part A, 3 mg [¹⁴C]-avenciguat single dose (oral solution); Part B, 3 mg unlabeled avenciguat (tablet) then 30 µg [¹⁴C]-avenciguat (intravenous). Primary endpoints: Part A, mass balance and recovery of [¹⁴C] radioactivity in excreta; Part B, absolute bioavailability. Safety and pharmacokinetics were evaluated.

RESULTS:

In Part A (N = 6), geometric mean recovery of [¹⁴C] radioactivity was 90.0% (range 80.6-96.0%). Elimination was mainly via feces (geometric mean 85.3%; range 76.5-91.3%); urine (4.66%; range 4.10-5.31%). In Part B (N = 6), the absolute bioavailability of avenciguat was 83.0%. In pooled plasma, the predominant drug-related component was avenciguat (mean 86.8%); the acyl glucuronide metabolite represented 5.2% of radioactivity. Drug-related adverse events (AEs) occurred in 33.3% (4/12) of participants, mostly mild, with one moderate presyncope event. No AEs leading to discontinuation were reported.

CONCLUSIONS:

Avenciguat was generally well tolerated and was primarily excreted unchanged in feces and minimally excreted in urine. After oral administration, avenciguat has high oral bioavailability.

CLINICAL TRIAL REGISTRATION:

ClinicalTrials.gov (NCT05515328).

2025-08-01·RHEUMATOLOGY

Avenciguat: a novel soluble guanylate cyclase activator that affects multiple cell types to inhibit IFN-1 signalling and fibrosis

Article

作者: Tran-Manh, Cuong ; Zhou, Xiang ; Kaufman, Julia ; Ebenezer, David L ; Nabozny, Gerald ; Wohnhaas, Christian T ; Liebel, Christoph ; Distler, Jörg H W ; Delic, Denis ; Trinh-Minh, Thuong ; Wang, Chao-Ting ; Daley, Lee-Anne

Abstract:

Objectives:

The soluble guanylate cyclase (sGC) stimulator riociguat is approved for the treatment of pulmonary arterial hypertension and may have antifibrotic effects. However, in fibrotic tissues, oxidative stress and hypoxia can render sGC insensitive to sGC stimulators. sGC activators overcome this limitation. Here, we characterize the novel sGC activator, avenciguat, in preclinical models of SSc.

Methods:

Human microvascular endothelial cells-dermal (HMVEC-d) cultured in hypoxic conditions and activated human platelet-rich plasma were incubated with varying doses of avenciguat, and the levels of TGF-β2 and human CXC chemokine family ligand 4 (CXCL4) were measured, respectively. Treatment with avenciguat was analysed in mice with bleomycin-induced dermal and pulmonary fibrosis.

Results:

Avenciguat reduced hypoxia-induced synthesis of TGF-β2 by HMVEC-d and inhibited CXCL4 release by platelets. Moreover, avenciguat demonstrated antifibrotic effects on bleomycin-induced dermal and pulmonary fibrosis. RNA sequencing of affected skin uncovered a unique profile distinguishing avenciguat from riociguat. Avenciguat treatment resulted in deeper regulation of IFN-1 signalling and genes associated with immune response vs riociguat treatment.

Conclusion:

In preclinical studies, avenciguat shows the potential to influence vascular, fibrotic and immune-related processes in murine models of SSc. These studies suggest that it may offer therapeutic benefit across multiple aspects of SSc pathophysiology and support the rationale for further investigation in a Phase II clinical trial (VITALISScE™; NCT05559580) of avenciguat in SSc.

2025-05-01·ANNALS OF INTERNAL MEDICINE

Nephrology: What You May Have Missed in 2024

Review

作者: Alkhajah, Hussa ; Sehgal, Ashwini R. ; Alfarsi, Razan ; Collins, Jhonna ; Alfadhel, Abdulla

This article highlights some important nephrology studies published in 2024 that may be relevant for nonnephrologist physicians. Four studies examined progression of chronic kidney disease (CKD), cardiovascular events, and nephrolithiasis with respect to use of semaglutide or sodium-glucose cotransporter-2 inhibitors. Three studies examined treatments to improve specific aspects of CKD management, including mineralocorticoid receptor agonists to address heart failure, avenciguat to address albuminuria, and oral phosphate binders to address fracture risk. One study demonstrated that inorganic nitrate reduced the risk for contrast-induced nephropathy. Finally, a trial of cefepime-taniborbactam showed benefit for treating complicated urinary tract infection.

8

项与 Avenciguat 相关的新闻（医药）

2026-04-27

·Doc 黄艳的科普

血管病变、免疫失调和进行性纤维化为特征的系统性硬化症治疗/阻纤、调免、护脉

系统性硬化症（SSc）是一种罕见的多系统自身免疫性疾病，以血管病变、免疫失调和进行性纤维化为特征，可导致严重的发病率和死亡率。其临床表现、疾病进展和治疗反应存在显著异质性，几乎所有患者都会出现雷诺现象（RP），约半数患者会发生指端溃疡（DUs）；肺部并发症[尤其是间质性肺病（ILD）和肺动脉高压（PAH）]是SSc相关死亡的主要原因，ILD累及高达80%的患者，25%-30%会发展为进行性表型，进而导致呼吸衰竭和死亡；胃肠道（GI）受累率高达90%，常累及食道、小肠和结肠，通过营养不良及其他并发症严重影响患者生活质量。甲氨蝶呤（MTX）：用于弥漫性皮肤系统性硬化症（dcSSc）的皮肤疾病治疗，但结果不一。在风湿病学中常用的较高剂量（高达25mg/周）的疗效仍有待明确。 MMF：现在被推荐为SSc-ILD的一线治疗药物，尤其适用于长期疾病稳定患者。生物制剂托珠单抗（TCZ）：FDA批准用于SSc-ILD。抗纤维化药物：尼达尼布（nintedanib）是一种酪氨酸激酶抑制剂，已成为SSc-ILD的重要抗纤维化药物，尤其适用于肺部进行性受累的患者。内皮素受体拮抗剂（ERAs）：包括安立生坦、波生坦和马昔腾坦，是PAH治疗的关键组成部分。磷酸二酯酶-5抑制剂（PDE-5i）：西地那非（SUPER-1研究）和他达拉非（PHRIST研究）在改善SSc-PAH患者的运动能力、生活质量和肺血流动力学方面显示出疗效。联合治疗：安立生坦和他达拉非联合治疗（AMBITION研究）已成为低至中风险患者的首选一线方案，其结局优于单药治疗。胃食管反流病（GERD）治疗质子泵抑制剂（PPIs）：仍是SSc患者GERD管理的基础，尽管缺乏强有力的证据。多潘立酮和海藻酸在与PPIs联合使用时显示出额外获益。新兴药物：沃诺拉赞（vonoprazan）是一种钾竞争性酸阻滞剂，在小型研究中显示出潜力，通过提高食管下括约肌压力和降低胃酸度，为PPI难治性病例提供了一种替代方案。小肠细菌过度生长（SIBO）治疗小肠细菌过度生长是SSc的常见并发症，通常采用周期性抗生素治疗。利福昔明（800-1200mg/天）被证明是其他抗生素疗效的两倍（症状缓解率77.8% vs 44.8%）。静注人免疫球蛋白（IVIG）已成为治疗SSc患者严重、难治性胃肠道受累的潜在治疗选择，尤其是在患有动力障碍、自身免疫性肠病或严重吸收不良的患者中。甲氨蝶呤仍然是治疗SSc相关关节炎最广泛使用的一线治疗药物。未来临床试验的优先目标 B细胞存活与活化机制原理：在自身抗体产生和免疫失调中起核心作用。代表性方法：BAFF/APRIL阻断（如贝利尤单抗、泰它西普）。临床重点：早期弥漫性SSc、自身抗体阳性患者。 CD19+B细胞耗竭机制原理：促进免疫重置和自身免疫控制。代表性方法：CD19定向CAR-T细胞疗法。临床重点：难治性SSc。 I型干扰素信号传导机制原理：与先天免疫激活和纤维化相关。代表性方法：IFNAR阻断（如阿尼鲁单抗/阿伏利尤单抗）。临床重点：免疫激活、早期dcSSc。 T细胞共刺激机制原理：OX40-OX40L促进致病性T效应细胞扩增。代表性方法：OX40L抑制剂（如Amlitelimab）。临床重点：SSc-ILD、皮肤纤维化。调节性T细胞增强机制原理：恢复免疫耐受，对抗炎症。代表性方法：低剂量IL-2疗法。临床重点：早期炎症性SSc。 IL-6通路机制原理：驱动成纤维细胞活化、炎症和肺部受累。代表性方法：IL-6抑制（如ziltivekimab、olokizumab）。临床重点：皮肤+ILD。结缔组织生长因子（CTGF）机制原理：作为TGF-β下游的纤维化介质。代表性方法：抗CTGF抗体（如pamrevlumab）。临床重点：SSc-ILD。溶血磷脂酸（LPA）信号传导机制原理：促进成纤维细胞募集、活化和纤维化。代表性方法：LPA1受体拮抗剂（如SAR100842）。临床重点：皮肤纤维化。黑皮质素受体激活（MC1R）机制原理：调节炎症和皮肤纤维化。代表性方法：MC1R调节剂（如MT-7117）。临床重点：炎症性皮肤病。磷酸二酯酶4B（PDE4B）机制原理：放大促炎细胞因子的产生。代表性方法：PDE4B抑制（如Nerandomilast）。临床重点：进行性SSc-ILD。 FcRn-IgG循环机制原理：维持循环中致病性自身抗体的水平。代表性方法：FcRn抑制以降低IgG负荷。临床重点：ILD、血管病变。内皮功能障碍/NO-sGC轴机制原理：血管舒张和内皮修复受损。代表性方法：sGC刺激剂（如Avenciguat）。临床重点：PAH、指端溃疡。双重免疫-纤维化作用机制原理：同时靶向免疫和基质驱动因素。代表性方法：双特异性抗体（如CD19/CD3、FAP/CD3）。临床重点：多领域疾病。免疫-纤维化协同作用（联合）机制原理：反映SSc的多因素发病机制。代表性方法：MMF+RTX+尼达尼布。临床重点：进行性SSc-ILD。延伸阅读手指遇冷就变色、发麻？这不是单纯的冻手冻脚，医学上叫雷诺现象类风湿不疼了就能停药？科学使用甲氨蝶呤的四个关键点！

2026-02-26

·FierceBiotech

Boehringer pens $500M pact with British biotech for oral approach to autoimmune diseases

Carine Boustany, Ph.D., head of immunology and respiratory diseases research at Boehringer Ingelheim, said autoimmune and inflammatory diseases “remain areas where innovation is urgently needed.” \n Boehringer Ingelheim has penned a $500 million deal with a British biotech for a preclinical program the German pharma hopes could offer a fresh oral treatment approach to a variety of autoimmune and inflammatory diseases.In return for the exclusive global license to Sitryx’s small molecule inhibitor program, the Oxford, England-based biotech could receive upfront and milestone payments in excess of $500 million, although the companies didn’t offer a breakdown of the financials. In addition, Sitryx will receive a slice of the royalties should a drug make it to market.Boehringer is banking on the program offering a new oral and precision approach to modulating disease-driving immune cells, the pharma explained in a Feb. 26 release.Autoimmune-focused Sitryx, which has a presence in Boston, launched in 2018 with the backing of GSK and SV Health Investors. Since then, Sitryx had been exploring the role of metabolic pathways in the function of immune cells, with Eli Lilly handing the biotech $50 million in 2020 for the rights to up to four autoimmune drugs. The pharma later took one of these drugs, an itaconate mimetic dubbed SYX-1042, into a phase 1 study before handing the asset back in August 2025 citing “strategic considerations and reprioritization of Lilly’s pain and inflammation portfolio.”The returned SYX-1042 is now the most advanced drug in Sitryx’s portfolio, followed by SYX-5219, a PKM2 modulator in phase 1 development for atopic dermatitis. The biotech’s preclinical pipeline includes a GLS1 inhibitor for allergic asthma and an SIK2 inhibitor for ulcerative colitis. Sitryx CEO Iain Kilty, Ph.D., said today’s deal with Boehringer marks a “major milestone for our company and is a clear validation of the strength of our pipeline and our expertise translating immunometabolic targets into meaningful therapeutic candidates.”“We are proud to out-license this preclinical program to Boehringer Ingelheim whose global capabilities in immunology and drug development will help position this program to deliver meaningful benefits to patients worldwide,” Kilty added.This morning’s agreement with Sityrx continues a busy few months of dealmaking for Boehringer. This year alone has already seen the German drugmaker pen a 1.05 billion euro ($1.26 billion) biobucks deal for Simcere’s preclinical inflammatory bowel disease bispecific antibody as well as a $120 million kidney-focused collaboration with Variant Bio.Meanwhile, the pharma’s existing clinical-stage immunology pipeline includes the likes of the sGC activator avenciguat for systemic sclerosis and a TREM-1 antagonist for ulcerative colitis.Carine Boustany, Ph.D., head of immunology and respiratory diseases research at Boehringer, said autoimmune and inflammatory diseases “remain areas where innovation is urgently needed.” “Sitryx’s small molecule inhibitor program brings forward a promising new mechanism that aligns with our focus on advancing first-in-class approaches,” Boustany added in the release. “Together with Sitryx, we are committed to translating this science into therapies that can meaningfully improve patients’ lives.”

引进/卖出临床1期免疫疗法

2026-01-26

·肾康汇

新兴治疗靶点：这两类肾病的病理机制及药物研发进展

点击箭头处“蓝色字”，关注我们哦！！新兴治疗靶点：这两类肾病的病理机制及药物研发进展代谢综合征和糖尿病患者高发代谢功能障碍相关肾病(metabolic dysfunction–associated kidney disease, MAKD)与糖尿病肾病(diabetic kidney disease, DKD)。尽管现有"四大支柱"疗法(RAAS抑制剂、SGLT2抑制剂、非甾体盐皮质激素受体拮抗剂、GLP-1受体激动剂)——已显著改善心肾结局，但仍无法完全遏制疾病进展。近期发表在权威期刊《Kidney International》上的这篇综述文章系统评述了针对肾小球血流动力学异常、内皮功能障碍、足细胞损伤与脂毒性、代谢性炎症及肾纤维化等核心病理生理环节的新兴治疗靶点，并剖析其临床转化前景。图：代谢功能障碍相关肾病(MAKD)和糖尿病肾病(DKD)的新兴潜在治疗靶点一、针对肾小球高滤过肾小球高滤过是DKD与肥胖相关性肾病的早期病理生理标志，其机制涉及入球与出球小动脉舒缩调控失衡。传统RAAS抑制剂通过减弱出球小动脉收缩降低肾小球内压，但无法完全逆转1型糖尿病(T1D)患者的高滤过状态。双重SGLT1/2抑制剂(如Sotagliflozin)通过恢复管球反馈(TGF)机制收缩入球小动脉，减轻高滤过。相比单纯SGLT2抑制可能提供额外肾脏保护。二、针对肾小球内皮功能障碍肾小球内皮细胞在维持血管张力、滤过屏障通透性及其与足细胞、系膜细胞的交互通讯中发挥核心作用。糖尿病状态下血管内皮生长因子A(VEGF-A)信号通路的异常活化导致新生血管形成与内皮功能紊乱。然而，抗VEGF疗法因治疗窗狭窄(过度抑制导致血栓性微血管病与蛋白尿加剧)而临床应用受限。KLF2激活剂可以增强内皮型一氧化氮合酶(eNOS)表达，改善内皮功能，减轻蛋白尿和肾小球损伤。鉴于KLF2在糖尿病肾小球内皮细胞中表达下调，该靶点兼具肾脏与心血管保护潜力。三、针对足细胞损伤与脂毒性足细胞作为滤过屏障的关键组分，其损伤与丢失是DKD与代谢障碍相关肾病的共同致病环节。现有研发管线涵盖多维度干预： 1、细胞因子与离子通道靶向 • 抗可溶性尿激酶型纤溶酶原激活物受体(suPAR)抗体(WAL0921)：通过中和循环suPAR减轻足细胞骨架损伤，已完成I期临床试验(NCT05891366)。 • 瞬时受体电位阳离子通道6(TRPC6)抑制剂(BI 764198)：阻断钙离子超载介导的calpain活化与自噬障碍，在BTBR ob/ob小鼠中验证有效，现处于IIa期临床试验(NCT05213624)。 • Dynamin GTP酶激活剂(Bis-T-23)：促进足细胞肌动蛋白聚合与骨架重塑，尚处临床前研究。 2、酪氨酸激酶受体调控 • TYRO3受体激动剂(C-10)：通过抑制凋亡与炎症通路保护足细胞，其在肾脏中的表达富集于足细胞，提示具有细胞特异性优势。 3、脂毒性干预足细胞脂质稳态失衡是DKD进展的重要驱动因素。他汀类药物的肾脏保护效应有限，凸显肾脏特异性脂质调控的重要性。 • ATP结合盒转运体A1(ABCA1)诱导剂：增强胆固醇外排，改善线粒体功能障碍，在db/db与Alport综合征模型中验证有效。 • 羟丙基-β-环糊精(VAR200)：通过螯合效应减少细胞内胆固醇蓄积，已进入DKD的IIa期开放标签研究(NCT06489340)，需警惕输注相关反应与肝毒性。 • 鞘磷脂酶样磷酸二酯酶3b(SMPDL3b)抑制：调节神经酰胺-1-磷酸水平，恢复足细胞胰岛素受体信号，在db/db小鼠中减轻蛋白尿。四、抑制代谢性炎症代谢性炎症(meta-inflammation)是连接代谢紊乱与肾脏损伤的桥梁。NLRP3炎症小体抑制剂(MCC950)可以阻断代谢紊乱与炎症的恶性循环，减轻足细胞损伤和脂质积累。但近期研究质疑其是否在足细胞中直接起效，可能主要通过免疫细胞发挥作用。五、阻断肾纤维化 TGF-β/Smad3通路是驱动肾小球硬化与肾小管间质纤维化的核心信号轴。泛TGF-β抗体因信号通路的细胞特异性与双向效应而临床失败。特异性Smad3抑制剂(SIS3)在T1D与T2D模型中显著减轻肾脏损伤。同源域相互作用蛋白激酶2(HIPK2)作为Smad3的共激活因子，其变构抑制剂BT173在肾纤维化模型中展现疗效，且HIPK2敲除小鼠无严重表型，提示该靶点具有更佳的安全性边际。六、其他新兴靶点与代谢重编程 • 可溶性鸟苷酸环化酶(sGC)激活剂(BI 685509)：在氧化应激状态下直接激活sGC，兼具血管、抗炎与抗纤维化效应，IIb期临床试验显示其可降低CKD与DKD患者蛋白尿(NCT04750577, NCT04736628)。 • HIF-脯氨酰羟化酶抑制剂(Enarodustat)：通过稳定缺氧诱导因子(HIF)促进促红细胞生成素合成，在BTBR ob/ob小鼠中改善糖脂代谢紊乱与肾脏能量代谢，II期临床试验中显示出肾脏保护信号。未来方向未来研究需聚焦于：①明确各靶点在人类疾病中的细胞特异性作用;②优化生物标志物指导的患者选择;③设计合理的联合用药方案以最大化心肾保护效应。通过深化病理机制认知与加速转化研究，有望突破当前治疗瓶颈，实现精准防控。参考文献 Li X, He JC, Lee K. New potential therapeutic targets of metabolic disorder-associated kidney disease and diabetic kidney disease. Kidney Int. 2026 Jan;109(1):81-88. 关注获取更多点赞分享在看留言

100 项与 Avenciguat 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肝硬化	临床2期	澳大利亚	Boehringer Ingelheim International GmbH	2024-02-27
肝硬化	临床2期	澳大利亚	Boehringer Ingelheim Pharma GmbH & Co., KG	2024-02-27
系统性硬皮病	临床2期	美国	勃林格殷格翰（中国）投资有限公司	2022-12-14
系统性硬皮病	临床2期	美国	Boehringer Ingelheim Pharma GmbH & Co., KG	2022-12-14
系统性硬皮病	临床2期	日本	Boehringer Ingelheim Pharma GmbH & Co., KG	2022-12-14
系统性硬皮病	临床2期	日本	勃林格殷格翰（中国）投资有限公司	2022-12-14
系统性硬皮病	临床2期	阿根廷	勃林格殷格翰（中国）投资有限公司	2022-12-14
系统性硬皮病	临床2期	阿根廷	Boehringer Ingelheim Pharma GmbH & Co., KG	2022-12-14
系统性硬皮病	临床2期	澳大利亚	Boehringer Ingelheim Pharma GmbH & Co., KG	2022-12-14
系统性硬皮病	临床2期	澳大利亚	勃林格殷格翰（中国）投资有限公司	2022-12-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05515328 (Pubmed \| Expert Opin Investig Drugs)	临床1期	-	12	Avenciguat 3 mg [14C]-avenciguat single dose (oral solution)	構願繭壓鑰範憲齋夢觸(衊顧齋鹹壓範簾繭夢壓) = 獵膚餘觸獵壓繭餘艱鹹選獵鏇齋淵積鹽艱壓夢 (齋糧鑰憲顧衊願壓艱繭 ) 更多	积极	2026-01-13
				Avenciguat 3 mg unlabeled avenciguat (tablet) then 30 μg [14C]-avenciguat (intravenous)	壓艱獵餘艱觸網廠淵糧(鏇襯淵鹹壓顧鹹鑰憲廠) = 繭選醖構膚鏇鹽選蓋憲製憲衊製膚鹽齋廠艱繭 (鬱襯艱顧觸窪淵遞艱構 )
NCT05161481 (CTgov)	临床2期	食管胃静脉曲张 \| 门静脉高血压 \| 高血压 ... 更多	80	Placebo matching Avenciguat (BI 685509) (Placebo)	窪鏇獵襯網鹽窪壓選艱(蓋鬱鏇選餘廠廠網鏇積) = 築製簾壓窪膚糧觸築憲鬱齋鹹築鏇艱願鹹壓願 (鹹齋衊鏇範憲窪築顧鑰, 壓壓鑰襯淵製餘鏇襯廠 ~ 願蓋網襯醖鏇製膚遞範) 更多	-	2025-06-15
				Avenciguat (BI 685509) (Avenciguat 2 mg BID)	窪鏇獵襯網鹽窪壓選艱(蓋鬱鏇選餘廠廠網鏇積) = 選襯積餘鹹鹽遞鏇艱積鬱齋鹹築鏇艱願鹹壓願 (鹹齋衊鏇範憲窪築顧鑰, 鬱襯衊構衊糧選網製顧 ~ 壓繭製艱鹹壓遞膚積憲) 更多
NCT06082843 (CTgov)	临床2期	酒精性肝硬化 \| 肝硬化	22	Placebo (Placebo)	遞構鹽蓋餘艱製構淵觸 = 製衊範簾鏇齋簾繭餘願餘窪鑰糧範繭遞鏇夢糧 (製築蓋齋獵顧廠膚製衊, 簾簾鬱觸積網膚齋繭餘 ~ 願鑰遞簾顧遞遞艱夢範) 更多	-	2025-06-12
				Avenciguat (Avenciguat)	遞構鹽蓋餘艱製構淵觸 = 鬱構淵積艱積鹹鏇壓夢餘窪鑰糧範繭遞鏇夢糧 (製築蓋齋獵顧廠膚製衊, 觸鹹選鑰夢壓襯範醖艱 ~ 繭夢鬱醖襯膚願構鬱觸) 更多
NCT05282121 (CTgov)	临床2期	甲型肝炎 \| 食管胃静脉曲张 \| 代谢功能障碍相关脂肪性肝炎 ... 更多	90	Avenciguat (Patients With HBV - Avenciguat)	網積獵願艱鑰壓構蓋糧(膚醖範構構膚衊顧積憲) = 鏇淵夢壓餘窪鬱遞願夢淵鏇繭糧鹹艱膚範蓋糧 (網製鹽繭醖選蓋網遞膚, 6.66) 更多	-	2025-04-29
				Avenciguat (Patients With HCV - Avenciguat)	網積獵願艱鑰壓構蓋糧(膚醖範構構膚衊顧積憲) = 鹹鹹獵窪顧獵獵壓構餘淵鏇繭糧鹹艱膚範蓋糧 (網製鹽繭醖選蓋網遞膚, 7.09) 更多
NCT04736628 (CTgov)	临床2期	非糖尿病慢性肾脏病	261	Avenciguat (Avenciguat 1 mg TID)	鹽選願範餘繭醖獵鬱膚(醖簾夢選構齋廠鹽艱壓) = 鬱窪糧壓餘鑰鬱憲餘製製願艱製蓋夢構膚繭窪 (艱繭蓋衊衊艱鹽憲製廠, 0.067) 更多	-	2024-09-04
				Avenciguat (Avenciguat 2 mg TID)	鹽選願範餘繭醖獵鬱膚(醖簾夢選構齋廠鹽艱壓) = 獵遞範構構衊艱築獵製製願艱製蓋夢構膚繭窪 (艱繭蓋衊衊艱鹽憲製廠, 0.068) 更多
NCT04750577 (CTgov)	临床2期	糖尿病肾病	243	BI 685509 (BI 685509 1 mg TID)	構夢糧艱膚顧選鹽夢構(積糧糧窪願廠願蓋夢願) = 夢齋餘鹽網製廠構艱鑰製窪衊壓窪膚艱網艱夢 (選襯壓鏇蓋鹹壓範鏇願, 0.074) 更多	-	2024-07-23
				BI 685509 (BI 685509 3 mg TID)	構夢糧艱膚顧選鹽夢構(積糧糧窪願廠願蓋夢願) = 積鹹憲範範網繭衊壓觸製窪衊壓窪膚艱網艱夢 (選襯壓鏇蓋鹹壓範鏇願, 0.076) 更多
NCT04750577 \| NCT04736628 (Two Randomized Placebo-Controlled Trials, Pubmed \| J Am Soc Nephrol)	临床2期	非糖尿病慢性肾脏病 \| 糖尿病肾病	500	Avenciguat 1 mg TID	鹽願窪顧築鹽簾鹽簾願(鑰壓憲襯鬱鏇鏇夢獵願) = 鑰觸顧齋鹽簾鑰獵餘衊積鹹鏇糧齋齋糧簾築膚 (簾顧襯餘廠構鹽蓋製憲, -26.4 ~ -3.0) 更多	积极	2024-05-25
				Avenciguat 2 mg TID	鹽願窪顧築鹽簾鹽簾願(鑰壓憲襯鬱鏇鏇夢獵願) = 窪鏇醖鏇壓憲範鹽範齋積鹹鏇糧齋齋糧簾築膚 (簾顧襯餘廠構鹽蓋製憲, -24.6 ~ -0.1) 更多
BI-685509 (ASN2022)	临床2期	糖尿病肾病	50	BI-685509 30 mpk/day	醖憲願鹽壓襯蓋鹽齋齋(膚醖衊網觸醖鑰憲鏇觸) = 選壓鹽餘衊願觸蓋齋構繭淵積淵鬱蓋餘積夢鬱 (選夢觸廠夢鹽窪獵鹹糧 ) 更多	积极	2022-11-05
				BI-685509 100 mpk/day	醖憲願鹽壓襯蓋鹽齋齋(膚醖衊網觸醖鑰憲鏇觸) = 夢淵夢鏇鏇鹹鏇顧鏇襯繭淵積淵鬱蓋餘積夢鬱 (選夢觸廠夢鹽窪獵鹹糧 ) 更多